Nanoparticle Platform Shows Progress in Flu Vaccine Development

Post Date: March 25, 2022 | Publish Date: March 22, 2022


A nanoparticle-based platform for vaccine development discovered  by experts at Cincinnati Children’s and licensed to the company Blue Water Vaccines Inc. shows signs, in mice, of success against HA1 influenza.

Ming Tan, PhD, Division of Infectious Diseases, served as principal investigator of the study, published in the journal Nano Research.

The paper describes the performance of the team’s S60-HA1 pseudovirus nanoparticles (PVNPs).

“The PVNPs are highly immunogenic, eliciting high titers of HA1-specific antibodies in mice and the mouse sera strongly inhibited hemagglutinations of homologous and heterologous influenza virus HA proteins,” the co-authors state.

Blue Water Vaccines is using the norovirus shell and protrusion (S&P) platform to develop BWV-301, a vaccine for gastroenteritis caused by norovirus or rotavirus infection.

“This latest publication highlights the versatility of the S&P platform beyond norovirus/rotavirus application and supports BWV’s exploration of utilizing the novel S&P platform to develop vaccine candidates against H1, H3, and Flu B infections,” the company states.

Read the Blue Water Vaccines announcement

Publication Information

Original Title:Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity
Published in:Nano Research
Publish date:March 22, 2022

Read the Study

About this blog

The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.